The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
The global Antivenom market was valued at US$ 959.2 million in 2023 and is anticipated to reach US$ 1283.7 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
This report aims to provide a comprehensive presentation of the global market for Antivenom, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antivenom.
Report Scope
The Antivenom market size, estimations, and forecasts are provided in terms of sales volume (K Vials) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antivenom market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antivenom manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- CSL
- Merck
- BTG
- Pfizer
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- Vins Bioproducts
- Bharat Serums and Vaccines
- Serum Biotech
- MicroPharm
- Segment by Type
- Polyvalent antivenom
- Monovalent antivenom
Segment by Application
- Non-profit Institutions
- Hospitals and Clinic
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antivenom manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antivenom in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Antivenom Market Overview
1.1 Product Overview and Scope of Antivenom
1.2 Antivenom Segment by Type
1.2.1 Global Antivenom Market Value Comparison by Type (2024-2030)
1.2.2 Polyvalent antivenom
1.2.3 Monovalent antivenom
1.3 Antivenom Segment by Application
1.3.1 Global Antivenom Market Value by Application: (2024-2030)
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinic
1.4 Global Antivenom Market Size Estimates and Forecasts
1.4.1 Global Antivenom Revenue 2019-2030
1.4.2 Global Antivenom Sales 2019-2030
1.4.3 Global Antivenom Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antivenom Market Competition by Manufacturers
2.1 Global Antivenom Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antivenom Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antivenom Average Price by Manufacturers (2019-2024)
2.4 Global Antivenom Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antivenom, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antivenom, Product Type & Application
2.7 Antivenom Market Competitive Situation and Trends
2.7.1 Antivenom Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antivenom Players Market Share by Revenue
2.7.3 Global Antivenom Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antivenom Retrospective Market Scenario by Region
3.1 Global Antivenom Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antivenom Global Antivenom Sales by Region: 2019-2030
3.2.1 Global Antivenom Sales by Region: 2019-2024
3.2.2 Global Antivenom Sales by Region: 2025-2030
3.3 Global Antivenom Global Antivenom Revenue by Region: 2019-2030
3.3.1 Global Antivenom Revenue by Region: 2019-2024
3.3.2 Global Antivenom Revenue by Region: 2025-2030
3.4 North America Antivenom Market Facts & Figures by Country
3.4.1 North America Antivenom Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antivenom Sales by Country (2019-2030)
3.4.3 North America Antivenom Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antivenom Market Facts & Figures by Country
3.5.1 Europe Antivenom Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antivenom Sales by Country (2019-2030)
3.5.3 Europe Antivenom Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antivenom Market Facts & Figures by Country
3.6.1 Asia Pacific Antivenom Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antivenom Sales by Country (2019-2030)
3.6.3 Asia Pacific Antivenom Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Antivenom Market Facts & Figures by Country
3.7.1 Latin America Antivenom Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antivenom Sales by Country (2019-2030)
3.7.3 Latin America Antivenom Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antivenom Market Facts & Figures by Country
3.8.1 Middle East and Africa Antivenom Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antivenom Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antivenom Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Antivenom Sales by Type (2019-2030)
4.1.1 Global Antivenom Sales by Type (2019-2024)
4.1.2 Global Antivenom Sales by Type (2025-2030)
4.1.3 Global Antivenom Sales Market Share by Type (2019-2030)
4.2 Global Antivenom Revenue by Type (2019-2030)
4.2.1 Global Antivenom Revenue by Type (2019-2024)
4.2.2 Global Antivenom Revenue by Type (2025-2030)
4.2.3 Global Antivenom Revenue Market Share by Type (2019-2030)
4.3 Global Antivenom Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antivenom Sales by Application (2019-2030)
5.1.1 Global Antivenom Sales by Application (2019-2024)
5.1.2 Global Antivenom Sales by Application (2025-2030)
5.1.3 Global Antivenom Sales Market Share by Application (2019-2030)
5.2 Global Antivenom Revenue by Application (2019-2030)
5.2.1 Global Antivenom Revenue by Application (2019-2024)
5.2.2 Global Antivenom Revenue by Application (2025-2030)
5.2.3 Global Antivenom Revenue Market Share by Application (2019-2030)
5.3 Global Antivenom Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL
6.1.1 CSL Corporation Information
6.1.2 CSL Description and Business Overview
6.1.3 CSL Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Antivenom Product Portfolio
6.1.5 CSL Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Antivenom Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 BTG
6.3.1 BTG Corporation Information
6.3.2 BTG Description and Business Overview
6.3.3 BTG Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BTG Antivenom Product Portfolio
6.3.5 BTG Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Antivenom Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Haffkine Bio-Pharmaceutical
6.5.1 Haffkine Bio-Pharmaceutical Corporation Information
6.5.2 Haffkine Bio-Pharmaceutical Description and Business Overview
6.5.3 Haffkine Bio-Pharmaceutical Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Haffkine Bio-Pharmaceutical Antivenom Product Portfolio
6.5.5 Haffkine Bio-Pharmaceutical Recent Developments/Updates
6.6 Rare Disease Therapeutics
6.6.1 Rare Disease Therapeutics Corporation Information
6.6.2 Rare Disease Therapeutics Description and Business Overview
6.6.3 Rare Disease Therapeutics Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Rare Disease Therapeutics Antivenom Product Portfolio
6.6.5 Rare Disease Therapeutics Recent Developments/Updates
6.7 Flynn Pharma
6.6.1 Flynn Pharma Corporation Information
6.6.2 Flynn Pharma Description and Business Overview
6.6.3 Flynn Pharma Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Flynn Pharma Antivenom Product Portfolio
6.7.5 Flynn Pharma Recent Developments/Updates
6.8 Vins Bioproducts
6.8.1 Vins Bioproducts Corporation Information
6.8.2 Vins Bioproducts Description and Business Overview
6.8.3 Vins Bioproducts Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Vins Bioproducts Antivenom Product Portfolio
6.8.5 Vins Bioproducts Recent Developments/Updates
6.9 Bharat Serums and Vaccines
6.9.1 Bharat Serums and Vaccines Corporation Information
6.9.2 Bharat Serums and Vaccines Description and Business Overview
6.9.3 Bharat Serums and Vaccines Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bharat Serums and Vaccines Antivenom Product Portfolio
6.9.5 Bharat Serums and Vaccines Recent Developments/Updates
6.10 Serum Biotech
6.10.1 Serum Biotech Corporation Information
6.10.2 Serum Biotech Description and Business Overview
6.10.3 Serum Biotech Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Serum Biotech Antivenom Product Portfolio
6.10.5 Serum Biotech Recent Developments/Updates
6.11 MicroPharm
6.11.1 MicroPharm Corporation Information
6.11.2 MicroPharm Antivenom Description and Business Overview
6.11.3 MicroPharm Antivenom Sales, Revenue and Gross Margin (2019-2024)
6.11.4 MicroPharm Antivenom Product Portfolio
6.11.5 MicroPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antivenom Industry Chain Analysis
7.2 Antivenom Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antivenom Production Mode & Process
7.4 Antivenom Sales and Marketing
7.4.1 Antivenom Sales Channels
7.4.2 Antivenom Distributors
7.5 Antivenom Customers
8 Antivenom Market Dynamics
8.1 Antivenom Industry Trends
8.2 Antivenom Market Drivers
8.3 Antivenom Market Challenges
8.4 Antivenom Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
